Bolu ilindeki testis kanserli hastaların retrospektif analizi
Küçük Resim Yok
Tarih
2015
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Tests kanseri (Tca) erkeklerde görülen ürogenital malignitelerin yaklaşık %20’sini, tüm erkek maligni- telerinin yaklaşık %1-2’sini oluşturmasına rağmen, 15-35 yaş arası en sık görülen solid kanserlerdir. Kriptorşi- dizm, testküler mikrolitasis, Klinifelter ve Down Sendromu Tca için risk faktörleridir. Tca’lerinin %95’i germinal dokudan köken alır. Bu tümörler seminomatöz ve nonseminomatöz (embriyonel hücreli karsinom, teratom, koryokarsinom, yolk kesesi tümörü) olarak iki gruba ayrılmaktadır. Biz bu çalışmada, bölgemizde yaşayan Tca tanısı almış hastaların genel özelliklerini ve tedavi seçenekle rini retrospektf olarak değerlendirmeyi amaçladık. Gereç ve Yöntemler: 01.01.2012-30.07.2013 tarihleri arasında Bolu Abant İzzet Baysal Üniversitesi Tıp Fakülte - si, tbbi onkoloji polikliniğine başvuran Tca’li hastaların demografk özellikleri ve tedavi seçenekleri retrospektf olarak değerlendirildi. Bulgular: Bu süre içinde median yaşı 31(22-45) yıl olan 15 hastanın başvurduğu bulundu. İlk başvuru şikayet olarak 11’nunda (%74) testste kitle, 2’sinde (%13) ağrı, 2’sinde (%13) kitle ile birlikte ağrı vardı. Hastaların 14’ünde tümör unilateral, 1’inde bilateraldi. Tümör boyutu ortalama 4(0.8-10) cm’di. Hastaların tümörlerinin 7’si seminomatöz, 7’si nonseminomatöz ve bilateral tümörlü hastanın sağ testsi seminomatöz, diğeri nonse - minomatöz histolojiye sahipt. Orşiektomi sonrası seminomatöz evre IA olan 2 hastaya karboplatn, 1 hastaya izlem, evre IB olan 2 hastaya karboplatn, 1 hastaya izlem, evre IIB olan 1 hastaya bleomisin, etoposid, sisplatn (BEP) kemoterapisi verildiği, nonseminomatöz evre IA 2 hastaya izlem, evre II ve üzeri hastalara ise BEP kemoterapisi verildiği görüldü. Sonuç: Bolu ilindeki Tca’li hastaların değerlendirildiği bu retrospektf analiz sonuçları literatür ile uyumlu bulundu. Türkiye verilerini elde edebilmek için diğer illerinde dahil edileceği, daha fazla hasta katlımıyla yapılacak çalışmaların gerekli olduğunu düşünmekteyiz.
Objectve: ATestcular cancer (Tca) consists of approximately %20 of urogenital malignancy in men, and approximately %1 to 2 of all male malignancies. Tca is the most common solid tumor in males aged between 15 to 35 years. There are many risk factors related to Tca such as cryptorchidism, testcular microlithiasis, klinefelter and Down syndrome. 95% of Tca is derived from germinal tssue. Germ cell tumor is classifed into two groups: seminomatous and nonseminomatous (embryonic carcinoma cell, teratoma, choriocarcinoma, yolk sac tumor). In this study, we aimed to evaluate general characteristcs and treatment modalites of the patents with diagnosis of Tca living in our region. Material and Methods: Demographic characteristcs and treatment modalites of the patents with Tca followed at Bolu Abant İzzet Baysal University Medicine Faculty, Medical Oncology outpatent clinic between 01.01.2012 and 30.07.2013 were evaluated retrospectvely. Results: Fifeen patents with median age of 31 (22-45) were included in the study. As the frst compliant, 11 patents (%74) reported a mass within the tests, 2 patents (%13) reported pain, and 2 patents (%13) claimed both pain and mass. The tumor was unilateral in 14 patents and bilateral in 1 patent. The median tumor size was 4 (0.8-10) cm. 7 patents had seminomatous histology and 7 patents had nonseminomatous histology. The patent with bilateral tumor had seminomatous histology in the right tests and nonseminomatous histology in the lef tests. Afer orchiectomy, two patents with seminomatous stage IA were given carboplatn and one patent was followed without chemotherapy; two patents with stage IB were given carboplatn and one patent was followed without chemotherapy; one patent with stage IIB was given bleomycin, etoposide, cisplatn (BEP) chemotherap; 2 patents with nonseminomatous stage IA were followed without chemotherapy; the patentswith stage II and above were given BEP chemotherapy. Conclusion: We concluded that our results were in consistent with the literature. We assumed that further studies are needed in other part of the country to obtain the data of Turkish populaton.
Objectve: ATestcular cancer (Tca) consists of approximately %20 of urogenital malignancy in men, and approximately %1 to 2 of all male malignancies. Tca is the most common solid tumor in males aged between 15 to 35 years. There are many risk factors related to Tca such as cryptorchidism, testcular microlithiasis, klinefelter and Down syndrome. 95% of Tca is derived from germinal tssue. Germ cell tumor is classifed into two groups: seminomatous and nonseminomatous (embryonic carcinoma cell, teratoma, choriocarcinoma, yolk sac tumor). In this study, we aimed to evaluate general characteristcs and treatment modalites of the patents with diagnosis of Tca living in our region. Material and Methods: Demographic characteristcs and treatment modalites of the patents with Tca followed at Bolu Abant İzzet Baysal University Medicine Faculty, Medical Oncology outpatent clinic between 01.01.2012 and 30.07.2013 were evaluated retrospectvely. Results: Fifeen patents with median age of 31 (22-45) were included in the study. As the frst compliant, 11 patents (%74) reported a mass within the tests, 2 patents (%13) reported pain, and 2 patents (%13) claimed both pain and mass. The tumor was unilateral in 14 patents and bilateral in 1 patent. The median tumor size was 4 (0.8-10) cm. 7 patents had seminomatous histology and 7 patents had nonseminomatous histology. The patent with bilateral tumor had seminomatous histology in the right tests and nonseminomatous histology in the lef tests. Afer orchiectomy, two patents with seminomatous stage IA were given carboplatn and one patent was followed without chemotherapy; two patents with stage IB were given carboplatn and one patent was followed without chemotherapy; one patent with stage IIB was given bleomycin, etoposide, cisplatn (BEP) chemotherap; 2 patents with nonseminomatous stage IA were followed without chemotherapy; the patentswith stage II and above were given BEP chemotherapy. Conclusion: We concluded that our results were in consistent with the literature. We assumed that further studies are needed in other part of the country to obtain the data of Turkish populaton.
Açıklama
Anahtar Kelimeler
Onkoloji, Üroloji ve Nefroloji
Kaynak
Bozok Tıp Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
5
Sayı
1
